These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 17942755)

  • 1. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma.
    Dispenzieri A; Kyle RA; Katzmann JA; Therneau TM; Larson D; Benson J; Clark RJ; Melton LJ; Gertz MA; Kumar SK; Fonseca R; Jelinek DF; Rajkumar SV
    Blood; 2008 Jan; 111(2):785-9. PubMed ID: 17942755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modeling.
    Wu V; Moshier E; Leng S; Barlogie B; Cho HJ; Jagannath S; Madduri D; Mazumdar M; Parekh S; Chari A
    Blood Adv; 2018 Jun; 2(12):1470-1479. PubMed ID: 29945937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma.
    Larsen JT; Kumar SK; Dispenzieri A; Kyle RA; Katzmann JA; Rajkumar SV
    Leukemia; 2013 Apr; 27(4):941-6. PubMed ID: 23183428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of involved/uninvolved free light chain ratio determined by Freelite and N Latex FLC assays for identification of high-risk smoldering myeloma patients.
    Henriot B; Rouger E; Rousseau C; Escoffre M; Sébillot M; Bendavid C; Minvielle S; Avet-Loiseau H; Decaux O; Moreau C
    Clin Chem Lab Med; 2019 Aug; 57(9):1397-1405. PubMed ID: 30973821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM).
    Mateos MV; Kumar S; Dimopoulos MA; González-Calle V; Kastritis E; Hajek R; De Larrea CF; Morgan GJ; Merlini G; Goldschmidt H; Geraldes C; Gozzetti A; Kyriakou C; Garderet L; Hansson M; Zamagni E; Fantl D; Leleu X; Kim BS; Esteves G; Ludwig H; Usmani S; Min CK; Qi M; Ukropec J; Weiss BM; Rajkumar SV; Durie BGM; San-Miguel J
    Blood Cancer J; 2020 Oct; 10(10):102. PubMed ID: 33067414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Analysis of serum free light chains κ/λ ratio and heavy/light chain pairs of immunoglobulin to the stratification of multiple myeloma according to Mayo Stratification of Myeloma and Revised International Staging System].
    Ščudla V; Balcárková J; Lochman P; Vincová M; Pika T; Minařík J; Zapletalová J; Jarošová M
    Vnitr Lek; 2016 Apr; 62(4):269-80. PubMed ID: 27250604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baseline serum B-cell maturation antigen levels predict time to disease progression for patients with smoldering multiple myeloma.
    Bujarski S; Goldwater MS; Regidor BS; Jew S; Daniely D; Swift RA; Eades BM; Emamy-Sadr M; Souther E; Li M; Wang C; Xu N; Chen H; Spektor TM; Berenson JR
    Eur J Haematol; 2021 Sep; 107(3):318-323. PubMed ID: 33993536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic factors associated with progression of smoldering multiple myeloma to symptomatic form.
    Rago A; Grammatico S; Za T; Levi A; Mecarocci S; Siniscalchi A; De Rosa L; Felici S; Bongarzoni V; Piccioni AL; La Verde G; Pisani F; Franceschini L; Paviglianiti AL; Caravita T; Petrucci MT; De Stefano V; Cimino G;
    Cancer; 2012 Nov; 118(22):5544-9. PubMed ID: 22786730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells.
    Pérez-Persona E; Vidriales MB; Mateo G; García-Sanz R; Mateos MV; de Coca AG; Galende J; Martín-Nuñez G; Alonso JM; de Las Heras N; Hernández JM; Martín A; López-Berges C; Orfao A; San Miguel JF
    Blood; 2007 Oct; 110(7):2586-92. PubMed ID: 17576818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance.
    Rajkumar SV; Kyle RA; Therneau TM; Melton LJ; Bradwell AR; Clark RJ; Larson DR; Plevak MF; Dispenzieri A; Katzmann JA
    Blood; 2005 Aug; 106(3):812-7. PubMed ID: 15855274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Involved/uninvolved heavy/light chain index can predict progression in transplanted multiple myeloma patients.
    Espiño M; Arteche-López A; Medina S; Muñoz-Calleja C; Blanchard MJ; Alegre A; López-Jiménez FJ; Villar LM
    Bone Marrow Transplant; 2017 Aug; 52(8):1206-1207. PubMed ID: 28581457
    [No Abstract]   [Full Text] [Related]  

  • 12. Immunoglobulin free light chains and solitary plasmacytoma of bone.
    Dingli D; Kyle RA; Rajkumar SV; Nowakowski GS; Larson DR; Bida JP; Gertz MA; Therneau TM; Melton LJ; Dispenzieri A; Katzmann JA
    Blood; 2006 Sep; 108(6):1979-83. PubMed ID: 16741249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis.
    Kourelis TV; Kumar SK; Gertz MA; Lacy MQ; Buadi FK; Hayman SR; Zeldenrust S; Leung N; Kyle RA; Russell S; Dingli D; Lust JA; Lin Y; Kapoor P; Rajkumar SV; McCurdy A; Dispenzieri A
    J Clin Oncol; 2013 Dec; 31(34):4319-24. PubMed ID: 24145344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Impact of Serum Heavy/Light Chain Pairs in Patients With Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: Long-Term Results From a Single Institution.
    Magnano L; Fernández de Larrea C; Elena M; Cibeira MT; Tovar N; Aróstegui JI; Pedrosa F; Rosiñol L; Filella X; Yagüe J; Bladé J
    Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e71-7. PubMed ID: 27013181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system.
    Snozek CL; Katzmann JA; Kyle RA; Dispenzieri A; Larson DR; Therneau TM; Melton LJ; Kumar S; Greipp PR; Clark RJ; Rajkumar SV
    Leukemia; 2008 Oct; 22(10):1933-7. PubMed ID: 18596742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical usefulness of free light chain concentration as a tumor marker in multiple myeloma.
    Kang SY; Suh JT; Lee HJ; Yoon HJ; Lee WI
    Ann Hematol; 2005 Sep; 84(9):588-93. PubMed ID: 15883850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Correlation between Morphological Typing and Monoclonality of Bone Marrow Plasma Cells and Its Diagnostic Value for High-Risk Smoldering Multiple Myeloma].
    Xiao HJ; Wang QJ; Wu S; Dai XB; Zhuang YP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Aug; 32(4):1146-1151. PubMed ID: 39192411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease.
    Kastritis E; Terpos E; Moulopoulos L; Spyropoulou-Vlachou M; Kanellias N; Eleftherakis-Papaiakovou E; Gkotzamanidou M; Migkou M; Gavriatopoulou M; Roussou M; Tasidou A; Dimopoulos MA
    Leukemia; 2013 Apr; 27(4):947-53. PubMed ID: 23183429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum free light chains for monitoring multiple myeloma.
    Mead GP; Carr-Smith HD; Drayson MT; Morgan GJ; Child JA; Bradwell AR
    Br J Haematol; 2004 Aug; 126(3):348-54. PubMed ID: 15257706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma.
    Ravi P; Kumar S; Larsen JT; Gonsalves W; Buadi F; Lacy MQ; Go R; Dispenzieri A; Kapoor P; Lust JA; Dingli D; Lin Y; Russell SJ; Leung N; Gertz MA; Kyle RA; Bergsagel PL; Rajkumar SV
    Blood Cancer J; 2016 Jul; 6(7):e454. PubMed ID: 27471870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.